Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
Publication|Articles|August 21, 2025
- Pharmaceutical Executive: August 2025
- Volume 45
- Issue 6
Pharmaceutical Executive: August 2025 Interactive Digital Edition
View the Pharmaceutical Executive August 2025 issue in an interactive format.
Advertisement
Click
Articles in this issue
about 1 year ago
The CAR-T Climbabout 1 year ago
2025 Emerging Pharma Leadersabout 1 year ago
An RNA-Guided Pathabout 1 year ago
Acceleration and Ambitionabout 1 year ago
Driving Disruption in Deliveryabout 1 year ago
Building Promise from Precisionabout 1 year ago
Determined Problem-Solverabout 1 year ago
Direct-to-Consumer Prescription Care Comes of Ageabout 1 year ago
How to Get Product Iteration Right in HealthcareAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Rebuilding Clinical Data Workflows for the AI Era
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5